Covaxin well tolerated, phase 3 data shows 77.8% efficacy against symptomatic Covid: Lancet

A week after the World Health Organisation (WHO) granted Emergency Use Listing (EUL) to Covaxin, a prestigious medical journal Lancet has stated that the phase 3 data of India’s first indigenously developed vaccine demonstrates 77.8% efficacy against symptomatic Covid-19. Its efficacy data also demonstrates 70.8% protection against all variants of SARS-CoV-2.

from https://ift.tt/30aDSMa
via IFTTT